MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-18-2022
CureVac N.V. Total Shareholders Equity 2011-2026 | CVAC
Annual Total Shareholders Equity CureVac N.V.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 688 M | 711 M | -42.8 M | 32.1 M | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 711 M | -42.8 M | 347 M |
Quarterly Total Shareholders Equity CureVac N.V.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 623 M | 675 M | 688 M | 695 M | - | 982 M | 711 M | 761 M | - | - | -42.8 M | - | - | - | 32.1 M | - | - | - | 103 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 982 M | -42.8 M | 523 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
5.1 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
24.3 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M | China |
 |
Coherus BioSciences
CHRS
|
61 M | $ 1.63 | -4.4 % | $ 191 M | USA |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
48.7 B | - | - | $ 96.9 B |  Britain |
 |
Enlivex Therapeutics Ltd.
ENLV
|
1.93 B | $ 0.73 | -0.03 % | $ 33.4 M |  Israel |
 |
Arcturus Therapeutics Holdings
ARCT
|
214 M | $ 7.83 | -5.21 % | $ 214 M | Israel |
 |
Athira Pharma
ATHA
|
27.8 M | - | - | $ 269 M | USA |
 |
Esperion Therapeutics
ESPR
|
-302 M | $ 3.12 | - | $ 649 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-14.6 M | - | 0.74 % | $ 768 M | Israel |
 |
Exelixis
EXEL
|
2.16 B | $ 51.1 | -0.37 % | $ 13.9 B | USA |
|
Forte Biosciences
FBRX
|
61 M | $ 23.96 | -2.84 % | $ 310 M | USA |
|
Galera Therapeutics
GRTX
|
3.97 M | - | -32.59 % | $ 7.61 M | USA |
 |
Karyopharm Therapeutics
KPTI
|
-293 M | $ 8.9 | 0.56 % | $ 1.08 M | USA |
 |
AbCellera Biologics
ABCL
|
967 M | $ 4.4 | -7.76 % | $ 1.31 B | Canada |
 |
Midatech Pharma plc
MTP
|
11.4 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 17.3 | -5.57 % | $ 809 M | USA |
 |
BioNTech SE
BNTX
|
19.2 B | $ 91.99 | -0.26 % | $ 22.2 B | Germany |
 |
Compugen Ltd.
CGEN
|
103 M | $ 3.03 | 6.32 % | $ 283 M | Israel |
 |
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | USA |
 |
Gilead Sciences
GILD
|
22.7 B | $ 132.06 | -0.74 % | $ 164 B | USA |
 |
Genmab A/S
GMAB
|
36.7 B | $ 26.9 | 1.32 % | $ 1.74 B |  Danmark |
 |
Genprex
GNPX
|
7.96 M | $ 0.86 | 1.2 % | $ 802 K | USA |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.59 M | $ 3.49 | -4.12 % | $ 5.75 M | Israel |
 |
Grifols, S.A.
GRFS
|
8.61 B | $ 7.79 | 1.04 % | $ 5.29 B |  Spain |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Fortress Biotech
FBIO
|
49.9 M | $ 2.3 | 3.14 % | $ 64.2 M | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
189 M | $ 21.57 | -0.55 % | $ 2.74 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
35.5 M | $ 9.24 | 36.48 % | $ 264 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |